Common Variants in the Lipoprotein Lipase Gene in Brazil: Association with Lipids and Angiographically Assessed Coronary Atherosclerosis

Lipoprotein lipase is the rate-limiting enzyme in the lipolysis of plasma triglyceride-rich lipoproteins. We studied six variants (T-93G, D9N, N291S, PvuII, HindIII and S447X) in the lipoprotein lipase (LPL) gene in 309 nondiabetic patients with angiographically assessed coronary artery disease and...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry and laboratory medicine Vol. 41; no. 10; pp. 1351 - 1356
Main Authors Rios, Domingos L. S., Vargas, André F., Ewald, Gisele M., Torres, Marco R., Zago, Alcides J., Callegari-Jacques, Sídia M., Hutz, Mara H.
Format Journal Article
LanguageEnglish
Published Berlin Walter de Gruyter 01.10.2003
New York, NY
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Lipoprotein lipase is the rate-limiting enzyme in the lipolysis of plasma triglyceride-rich lipoproteins. We studied six variants (T-93G, D9N, N291S, PvuII, HindIII and S447X) in the lipoprotein lipase (LPL) gene in 309 nondiabetic patients with angiographically assessed coronary artery disease and in 197 controls in a southern Brazilian population of European descent. The HindIII H-allele was associated with lower triglycerides (p < 0.01) and higher high-density lipoprotein cholesterol (p = 0.03) levels, and the S447X mutation was associated with lower triglyceride levels (p < 0.01) in males, but not females. No other significant lipid associations were observed. Haplotypes were derived from these two sites (HindIII/S447X), and carriers of H-S and H-X haplotypes showed lower triglycerides (p < 0.01) and increased highdensity lipoprotein cholesterol (p = 0.01) levels when compared to the H+S haplotype in males. In this gender, the H-X haplotype was associated with a protective effect (OR = 0.36, 95%CI = 0.13-0.97) for significant disease (≥60% of luminal coronary stenosis), even controlling for other classical risk factors. Clin Chem Lab Med 2003; 41(10):13511356
Bibliography:istex:4DDF506D2CEA329BA9E5B886814DA1A3348491F5
cclm.2003.207.pdf
ArticleID:cclm.41.10.1351
ark:/67375/QT4-W0T8347T-H
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1434-6621
1437-4331
DOI:10.1515/CCLM.2003.207